Dove Medical Press podcasts

Welcome to the Dove Medical Press podcast series where hot topics in the world of medical research are discussed by those who know it best.

Dove Medical Press podcasts is a health podcast hosted by Dove Medical Press, with 33 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Dove Medical Press hosts Dove Medical Press podcasts, a health show with 33 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #3

  Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments

  Jul 2, 202521 minS1

  <p>This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and clinical data from key trials that underscore the clinical benefits of these targeted therapies. Through discussion of key findings from pivotal clinical trial studies, including data supporting the use of these agents in both newly diagnosed and relapsed or refractory (R/R) settings, the episode highlights significant outcomes such as increased overall response and prolonged duration of remission in patients treated with IDH1...

  ListenShow Notes
• 

  Episode #2

  Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML

  Jul 2, 202521 minS1

  <p>Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by diverse genetic mutations, including IDH1 and IDH2, which are present in approximately 15-20% of cases. Recent clinical practice guidelines, including the 2025 NCCN guidelines, emphasize the importance of comprehensive mutational profiling at diagnosis and at relapse to guide targeted treatment strategies for patients with refractory or relapsed (R/R) AML. IDH1-mutations, which occur in 5-7% of AML cases, result in the production of the oncometabolite 2-hydroxyglutarate (2-HG), disrupting cellular differentiation. IDH1-inhibitors, such as ivosidenib and olutasidenib, block this aberrant metabolic pathway, allowing for differentiation and apoptosis of leukemia...

  ListenShow Notes
• 

  Episode #1

  Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists

  Jun 22, 202527 minS1

  <p>Experts from Yale Cancer Center and MD Anderson Cancer Center describe the evolving landscape of molecular diagnostics in acute myeloid leukemia (AML). The discussion traces the shift from morphology- and immunophenotype-based classification to genomics-driven stratification, catalyzed by advancements in next-generation sequencing (NGS). Discussants emphasize the clinical importance of identifying key genetic mutations—such as FLT3, IDH1/2, TP53, NPM1, KMT2A, and NUP98—to inform prognosis and guide use of targeted therapies. They review the sensitivity and applications of testing modalities including Sanger sequencing, NGS, PCR, and capillary electrophoresis, and highlight how combining DNA and RNA analyses enhances detection of both...

  ListenShow Notes
• 

  Episode #5

  Exploring the Chronic Nature of Generalized Pustular Psoriasis

  Feb 2, 202520 minS1

  <p>Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease characterized by persistent symptoms and sudden flares of painful, sterile pustules, and may be accompanied by systemic inflammation. Ongoing symptoms of GPP can have a serious impact on patient quality of life, morbidity, and mortality, and severe flares may be life-threatening if left untreated. Guidelines have been developed for the treatment of GPP flares; however, health care professionals and patients are lacking guidance on the management of long-term, persistent symptoms of GPP. Spesolimab is the only FDA-approved treatment for GPP and is approved for use in adults and...

  ListenShow Notes
• 

  Episode #1

  Exploring the clinical presentation, course, and burden of disease in generalized pustular psoriasis

  Feb 28, 202418 minS1

  <p>Dr Uwe Wollina, the former head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Merola and Amin to discuss the potential triggers of an acute GPP flare. GPP can be debilitating for patients, and they will discuss the different aspects of the burden of disease for patients with GPP.</p> <p>Generalized pustular psoriasis (GPP) is the most severe form of pustular psoriasis and affects large areas of the body. GPP is a rare disease, and has a variable presentation; thus, its diagnosis is challenging. The onset of symptoms is rapid, with...

  ListenShow Notes

Recent guests on Dove Medical Press podcasts. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.